» Articles » PMID: 6287931

Pharmacokinetics and Tolerance of Ceftriaxone in Humans After Single-dose Intramuscular Administration in Water and Lidocaine Diluents

Overview
Specialty Pharmacology
Date 1982 Jun 1
PMID 6287931
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of 1% lidocaine as a diluent on the pharmacokinetics and tolerance of ceftriaxone administered intramuscularly were investigated in 12 adult volunteers. Each subject received two 0.5-g doses of ceftriaxone (one in water and the other in 1% lidocaine) at least 1 week apart in a randomized crossover fashion. Plasma and urine samples were collected serially and assayed for ceftriaxone content by high-performance liquid chromatography. The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 micrograms/ml, 2.5 h, 578 micrograms . h/ml, and 7.1 h, respectively, after intramuscular administration of ceftriaxone in water diluent. The corresponding mean values in 1% lidocaine diluent were 42 micrograms/ml, 3 h, 577 micrograms . h/ml, and 7.0 h. The pharmacokinetic data suggested that 1% lidocaine does not alter either the elimination parameters or the bioavailability of intramuscularly administered ceftriaxone. The intensity and frequency of pain at the injection site were reduced considerably by the coadministered lidocaine.

Citing Articles

Determination of ceftriaxone in human plasma using liquid chromatography-tandem mass spectrometry.

Wongchang T, Winterberg M, Tarning J, Sriboonvorakul N, Muangnoicharoen S, Blessborn D Wellcome Open Res. 2022; 4:47.

PMID: 36035377 PMC: 9379334. DOI: 10.12688/wellcomeopenres.15141.3.


Anesthetic Efficacy of Lidocaine/Ketorolac in Inferior Alveolar Nerve Block in Patients with Irreversible Pulpitis: A Randomized Clinical Trial.

Faghihian H, Faghihian R, Khademi A, Aggarwal V Eur Endod J. 2020; 5(3):186-190.

PMID: 33353921 PMC: 7881381. DOI: 10.14744/eej.2020.74946.


Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial.

Garcia-Prats A, Rose P, Draper H, Seddon J, Norman J, McIlleron H Pediatr Infect Dis J. 2018; 37(12):1199-1203.

PMID: 29561515 PMC: 6138584. DOI: 10.1097/INF.0000000000001983.


Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes.

Houlihan S, Decarie D, Benes C, Cleve R, Vidler M, Magee L J Obstet Gynaecol Can. 2016; 38(10):936-944.e3.

PMID: 27720093 PMC: 5461222. DOI: 10.1016/j.jogc.2016.04.097.


Validation and Application of a Dried Blood Spot Ceftriaxone Assay.

Page-Sharp M, Nunn T, Salman S, Moore B, Batty K, Davis T Antimicrob Agents Chemother. 2015; 60(1):14-23.

PMID: 26438505 PMC: 4704204. DOI: 10.1128/AAC.01740-15.


References
1.
Greenblatt D, Koch-Weser J . Intramuscular injection of drugs. N Engl J Med. 1976; 295(10):542-6. DOI: 10.1056/NEJM197609022951006. View

2.
SONNEVILLE P, Albert K, Skeggs H, Gentner H, Kwan K, Martin C . Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin. Eur J Clin Pharmacol. 1977; 12(4):273-9. DOI: 10.1007/BF00607426. View

3.
Benowitz N, Meister W . Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978; 3(3):177-201. DOI: 10.2165/00003088-197803030-00001. View

4.
FOSTER T, Shrewsbury R, Coonrod J . Bioavailability and pain study of cefamandole nafate. J Clin Pharmacol. 1980; 20(8-9):526-33. DOI: 10.1002/j.1552-4604.1980.tb02546.x. View

5.
Seddon M, Wise R, Gillett A, Livingston R . Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980; 18(2):240-2. PMC: 283977. DOI: 10.1128/AAC.18.2.240. View